QR code

Glutaminase inhibitor CB-839 causes metabolic adjustments in colorectal cancer cells

Abstract Colorectal cancer (CRC) cells are ‘addicted’ to glutamine to satisfy energy and biosynthetic needs. Inhibiting glutamine metabolism enzymes, like glutaminase, is a potential cancer therapy strategy. Although the GLS inhibitor CB-839 is being evaluated in clinical trials, a comprehensive ass...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Martina Spada, Cristina Piras, Vera Piera Leoni, Mattia Casula, Gabriella Simbula, Antonio Noto, Katia Lilliu, Karolina Krystyna Kopeć, Gabriele Serreli, Federica Murgia, Federica Etzi, Tinuccia Dettori, Luigi Atzori, Paola Caria
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Portfolio 2025-10-01
Reeks:Scientific Reports
Onderwerpen:
Colorectal cancer
Glutamine metabolism
CB-839
Glutaminolysis
Glutaminase-1 inhibition
Energetic metabolism
Online toegang:https://doi.org/10.1038/s41598-025-20528-2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items